<DOC>
	<DOCNO>NCT00856388</DOCNO>
	<brief_summary>This clinical trial study well give fludarabine phosphate melphalan together total-body irradiation follow donor stem cell transplant work treat patient hematologic cancer bone marrow failure disorder . Giving low dos chemotherapy total-body irradiation donor peripheral blood stem cell transplant help stop growth cancer cell abnormal cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer abnormal cell ( graft-versus-tumor effect )</brief_summary>
	<brief_title>Fludarabine Phosphate , Melphalan , Total-Body Irradiation , Donor Stem Cell Transplant Treating Patients With Hematologic Cancer Bone Marrow Failure Disorders</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine transplant relate mortality ( TRM ) reduce intensity transplantation ( RIT ) combination patient population usually eligible full myeloablative allogeneic transplant . SECONDARY OBJECTIVES : I . To evaluate engraftment , safety , clinical response , evidence graft-versus-malignancy effect/graft-versus-host disease ( GVHD ) overall outcome treatment RIT regimen across variety hematological condition . OUTLINE : Patients receive fludarabine phosphate intravenously ( IV ) 30 minute day -5 -2 melphalan* IV 30 minute day -2 . Patients undergo total-body irradiation day -1 allogeneic stem cell transplantation day 0 . Note : *Patients chromosomal breakage syndrome , Fanconi anemia dyskeratosis congenita , receive anti-thymocyte globulin IV 4 hour day -4 -2 instead melphalan . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Leukemia , Neutrophilic , Chronic</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Diagnosis histology document hematologic malignancy marrow disorder Bone marrow failure disorder nonmalignant hematologic immunologic disorder : Acquired bone marrow failure disorder include aplastic anemia , paroxysmal nocturnal hemoglobinuria ( PNH ) : Primary allogeneic hematopoietic stem cell transplantation ( HSCT ) appropriate select patient severe aplastic anemia ; however , patient aplastic anemia must fail least one cycle standard immunosuppressive therapy calcineurin inhibitor plus antithymocyte globulin ( ATG ) fullymatched donor available Patients PNH must history thrombosis relate PNH Hereditary bone marrow failure disorder include Fanconi anemia relate chromosomal breakage syndrome dyskeratosis congenita , DiamondBlackfan anemia , ShwachmanDiamond syndrome , Kostmann syndrome , congenital amegakaryocytic thrombocytopenia : Fanconi anemia relate chromosomal breakage syndrome : positive chromosome breakage analysis use diepoxybutane ( DEB ) mitomycin C applicable Dyskeratosis : diagnosis support use either telomerase reverse transcriptase ( TERC ) gene mutation autosomal dominant Dyskeratosis Congenita Xlinked DKC1 gene mutation Other nonmalignant hematologic immunologic disorder require transplantation Quantitative qualitative congenital platelet disorder ( include limit congenital amegakaryocytopenia , absentradii syndrome , Glanzmann 's thrombasthenia ) Quantitative qualitative congenital neutrophil disorder ( include limit chronic granulomatous disease , congenital neutropenia ) Congenital primary immunodeficiency ( include limit Severe Combined Immunodeficiency Syndrome , WiskottAldrick syndrome , CD40 ligand deficiency , Tcell deficiency ) Acute leukemia : Subjects must ineligible conventional myeloablative transplantation ; Resistant recurrent disease least one standard combination chemotherapy regime first remission patient high risk relapse OR First remission patient high risk relapse : Acute myeloid leukemia ( AML ) antecedent myelodysplastic syndrome , secondary AML , high risk cytogenetic abnormality normal cytogenetics highrisk molecular feature ( e.g . Flt3ITD mutation , mixedlineage leukemia [ MLL ] , wildtype NPM1 ) ; Acute lymphocytic leukemia ( ALL ) high standard risk ALL Chronic Myeloid Leukemia ( CML ) : Chronic phase ( intolerant unresponsive imatinib and/or tyrosine kinase inhibitor ) , second chronic phase accelerate phase ineligible conventional myeloablative transplantation Myeloproliferative myelodysplastic syndrome ( MDS ) : Myelofibrosis ( with/without splenectomy ) intermediate high risk feature Advanced polycythemia vera respond standard therapy MDS international prostate symptom score ( IPSS ) score Int2 high MDS low IPSS score Int1 le severe clinical feature severe neutropenia thrombocytopenia high risk chromosome abnormality monosomy 7 Secondary massively parallel signature sequence ( MPSS ) IPSS score Chronic myelomoncytic leukemia Lymphoproliferative disease : Chronic lymphocytic leukemia ( CLL ) , lowgrade nonHodgkin lymphoma ( NHL ) ( recurrent persistent ) fludarabine refractory le 6 month duration complete response ( CR ) course conventional therapy Multiple myeloma , progressive disease autologous stem cell transplant plan tandem ( allogeneic transplant prior autologous stem cell transplant ) Waldenstroms macroglobulinemia ( fail one standard regimen ) High grade NHL diffuse large Bcell lymphoma ( DLBCL ) Not eligible conventional myeloablative HSCT OR fail autologous HSCT First remission lymphoblastic lymphoma , small , noncleaved cell lymphoma mantle cell lymphoma Hodgkin disease : Relapsed refractory frontline therapy Failed eligible autologous transplantation Failed prior autotransplant Age &gt; = 3 = &lt; 75 year blood bone marrow transplant age &gt; = 3 , &lt; 60 cord blood transplant No serious uncontrolled psychiatric illness No concomitant active malignancy nonmelanoma skin cancer Nonpregnant nonnursing woman ( woman men reproductive potential agree use effective mean birth control ) Patients may receive prior autologous bone marrow transplant ( BMT ) prior myeloablative allogeneic BMT ( least 60 day elapse ) At least 2 week since prior chemotherapy , radiation treatment and/or surgery Informed consent DONOR : Permissible HLA matching : Related donor single antigen mismatch HLA A , B DRB 1 ; unrelated donor single antigen mismatch HLA A , B , C , +/ additional single allele level mismatch A , B , C DRB1 ; cord blood &gt; = 4 6 antigen match HLA A , B , DRB1 ) DONOR : Compatibility four informative HLA locus : A , B , C DRB1 important reduce risk GVHD successful transplant outcome ; A , B , C DRB1 loci comprise 8 possible allele ( haplotype inherit parent ) ; one additional locus , HLADQ , also type ascertain haplotype assist search compatible donor ; however mismatch DQ show associated adverse outcome ; high resolution molecular typing ( allele level ) standard care unrelated donor search allow great refinement search strategy DONOR : Matched relate donor : single antigen mismatch A , B , DR transplant family member associate high risk GVHD similar overall survival compare full identity 3 region ; relate donor/recipient pair must match 5 6 HLA antigen ( A , B , DRBl ) DONOR : Unrelated donor : evaluating patient unrelated donor transplant , high degree matching prefer due minimize risk GVHD ; A , B , C , DRB1 DQ locus , comprise 10 possible allele , type routinely unrelated transplant ; give high risk TRM mismatch transplant , RIT often best way mitigate risk ; evolve data National Marrow Donor Program make possible estimate risk donorrecipient HLA mismatch allele antigen level ; high risk HLAmismatching must carefully assess respect clinical urgency patient 's risk transplant physician ; antigen level mismatch DQ inconsequential transplant outcome ignore respect donor selection purpose protocol , match requirement confine 8 locus involve HLA A , B , C DRB1 ; purpose protocol , single antigen mismatch HLA A , B , C , without additional single allele level mismatch may participate protocol voluntary unrelated donor ( blood marrow ) ; patient must least antigenlevel match DRB1 DONOR : If patient suitable family donor match 5 6 HLA antigen ( A , B , DRB1 ) suitable unrelated donor identify reason urgency , patient consider candidate cord blood transplant , provide cord blood donor identify &gt; = 4 6 antigen match HLA A , B , DRB1 antigens ; cord blood product must provide minimum 2 x 10^7 nucleated cells/kg , test negative HIV Hepatitis A , Band C , sterility assay growth ; cord blood product locate National Marrow Donor Program , American Registry , Bone Marrow Donor Worldwide establish registry , may store N.Y Placental Cord Blood Bank , St. Louis Cord Blood Bank , establish , register International blood marrow bank DONOR : Donor must healthy nonreactive test result infectious disease assay require state federal regulation ; donor screen seropositive hepatitis and/or syphilis must clear infectious disease consultation DONOR : The donor must uncontrolled cardiopulmonary , renal , endocrine , hepatic psychiatric disease render donation unsafe DONOR : The donor must able give informed consent peripheral blood stem cell collection bone marrow collection DONOR : Syngeneic donor eligible DONOR : Donors poor peripheral venous access , may require central venous line placement stem cell apheresis Uncontrolled central nervous system ( CNS ) disease ( hematologic malignancy ) Karnofsky ( adult ) Lansky ( = &lt; 16 year ) performance status = &lt; 50 % Diffusing capacity lung carbon monoxide ( DLCO ) less 40 % predict , correct hemoglobin ( Hb ) and/or alveolar ventilation Cardiac : leave ventricular ejection fraction le 40 % Bilirubin &gt; = 3 x upper limit normal Liver alkaline phosphatase &gt; = 3 x upper limit normal Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvate transaminase ( SGPT ) &gt; = 3 x upper limit normal Child 's class B C liver failure Calculated creatinine clearance &lt; 40 cc/min modify CockcroftGault formula adult Schwartz formula pediatrics Patients receive maximally allow dos ( give 2 Gy fraction , equivalent ) previous radiation therapy various organ follow : Mediastinum 40 Gy Heart ( volume ) 36 Gy Whole lungs 12 Gy Small bowel ( volume ) 46 Gy Kidneys 12 Gy Whole liver 20 Gy Spinal cord ( volume ) 36 Gy Whole brain 30 Gy Enrollment patient previously receive high allow dose radiation small volume lung , liver , brain determine discretion radiation oncologist study Uncontrolled diabetes mellitus , cardiovascular disease , active serious infection condition , opinion treat physician , would make protocol unreasonably hazardous patient Human immunodeficiency virus ( HIV ) positive Patients opinion treat physician unlikely comply restriction allogeneic stem cell transplantation base formal psychosocial screening Females childbearing potential positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>